LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

7.35 1.52

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.23

Max

7.47

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

-968K

104M

P/E

Sektora vidējais

100.714

66.845

Peļņas marža

1.458

Darbinieki

1,515

EBITDA

8.6M

32M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+38.12% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 4. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

89M

1.1B

Iepriekšējā atvēršanas cena

5.83

Iepriekšējā slēgšanas cena

7.35

Ziņu noskaņojums

By Acuity

50%

50%

162 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. marts 23:39 UTC

Karstas akcijas

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

2026. g. 4. marts 23:20 UTC

Peļņas

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

2026. g. 4. marts 21:43 UTC

Peļņas

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

2026. g. 4. marts 23:48 UTC

Tirgus saruna

Nikkei May Rise After Recent Selloffs -- Market Talk

2026. g. 4. marts 23:33 UTC

Tirgus saruna
Galvenie ziņu notikumi

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

2026. g. 4. marts 23:24 UTC

Tirgus saruna

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

2026. g. 4. marts 22:30 UTC

Peļņas

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

2026. g. 4. marts 22:30 UTC

Peļņas

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

2026. g. 4. marts 22:30 UTC

Peļņas

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

2026. g. 4. marts 22:13 UTC

Peļņas

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

2026. g. 4. marts 22:13 UTC

Peļņas

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

2026. g. 4. marts 22:13 UTC

Peļņas

Vermilion Energy 4Q EPS C$2.86 >VET

2026. g. 4. marts 22:04 UTC

Tirgus saruna

RBA Slipping Behind The Curve On Rates -- Market Talk

2026. g. 4. marts 21:53 UTC

Peļņas

Lithium Americas 4Q Rev $66.8M >LAC

2026. g. 4. marts 21:53 UTC

Peļņas

Lithium Americas 4Q Loss/Shr 52c >LAC

2026. g. 4. marts 21:52 UTC

Peļņas

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

2026. g. 4. marts 21:50 UTC

Peļņas

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

2026. g. 4. marts 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 4. marts 21:48 UTC

Peļņas

Webull 4Q Rev $165.2M >BULL

2026. g. 4. marts 21:48 UTC

Peļņas

Webull 4Q EPS 1c >BULL

2026. g. 4. marts 21:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 4. marts 21:45 UTC

Tirgus saruna

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

2026. g. 4. marts 21:40 UTC

Peļņas

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

2026. g. 4. marts 21:36 UTC

Galvenie ziņu notikumi

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

2026. g. 4. marts 21:27 UTC

Peļņas

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

2026. g. 4. marts 21:17 UTC

Tirgus saruna

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

2026. g. 4. marts 21:16 UTC

Peļņas

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

2026. g. 4. marts 21:15 UTC

Peļņas

Broadcom 1Q EPS $1.50 >AVGO

2026. g. 4. marts 21:15 UTC

Peļņas

Broadcom 1Q Net $7.35B >AVGO

2026. g. 4. marts 21:15 UTC

Peļņas

Broadcom 1Q Rev $19.31B >AVGO

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

38.12% augšup

Prognoze 12 mēnešiem

Vidējais 10 USD  38.12%

Augstākais 13 USD

Zemākais 7 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

5

Pirkt

5

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

162 / 351 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat